> ## Content Index
> Fetch the complete content index at: https://med-techinsights.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# SetPoint Medical raises $140M to support commercialisation of RA therapy
- URL: https://med-techinsights.com/setpoint-medical-raises-140m-to-commercialise-ra-therapy/
- Published: 2025-08-12T14:00:13.000Z
- Updated: 2026-10-23T02:36:36.000Z
- Description: SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, has announced that it has raised 140 million USD in private financing, that will support commercialisation of the SetPoint System, a first-of-its-kind neuroimmune modulation therapy for
- Author: Oliver Johnson
- Tags: Medical Device Manufacturing, News

[**SetPoint Medical**](https://setpointmedical.com/?ref=med-techinsights.com), a company dedicated to developing therapies for people living with chronic autoimmune diseases, has announced that it has raised 140 million USD in private financing, that will support commercialisation of the SetPoint System, a first-of-its-kind neuroimmune modulation therapy for adults living with moderate-to-severe rheumatoid arthritis (RA), as well as advancement of the company’s pipeline in other autoimmune conditions.

The 140 million USD includes 25 million USD in the second tranche of its Series C financing, as well as 115 million USD in its Series D financing, co-led by Elevage Medical Technologies and Ally Bridge Group.

In conjunction with the Series D financing, Josh Makower, M.D., joined SetPoint Medical’s board of directors as a representative of Elevage Medical Technologies, along with Kevin Reilly, Managing Director and Head of MedTech investments at Ally Bridge Group.

New investors Northwell Health, SPRIG Equity and an undisclosed strategic investor also participated in the Series D financing, along with returning investors Norwest, New Enterprise Associates (NEA), Viking Global Investors, Action Potential Venture Capital, Abbott, Boston Scientific, Euclidean Capital, Richard King Mellon Foundation, Morgenthaler Ventures, ShangBay Capital, Ascendum Capital, Catalio Capital Management, Gilmartin Capital, and Midas Capital.

![](https://storage.ghost.io/c/98/19/9819191a-690e-400b-bf27-720adfd33f45/content/images/2026/10/14076-SETPOINT_image_for_press_release.jpg)

In preparation for commercialisation, SetPoint has announced two new executive appointments. Erik Styacich, former Vice President of Sales for neuromodulation company, Valencia Technologies, joins as Vice President of Sales, and Spencer Bailey joins as Vice President of Market Access & Reimbursement, after holding several similar leadership roles at other neuromodulation companies, including MicroTransponder, Inc.

“We are pleased to share these strategic milestones underpinning our commitment to a successful and seamless market launch for the SetPoint System in select U.S. markets this year, with broader national expansion in 2026,” added Murthy V. Simhambhatla, Ph.D., CEO of SetPoint Medical. “We are thrilled to welcome an outstanding group of new investors to our exceptional syndicate.”